RMD Quote, Financials, Valuation and Earnings

Intuitive Surgical, Inc. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 27.89%. ResMed, Inc.'s return on equity of 25.6% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

ResMed, Inc. has a consensus price target of $292.67, signalling upside risk potential of 13.56%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 17.2%. Given that Intuitive Surgical, Inc. has higher upside potential than ResMed, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.88%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. ResMed, Inc.'s net income of $348.5M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, ResMed, Inc.'s price-to-earnings ratio is 26.38x while Intuitive Surgical, Inc.'s PE ratio is 66.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.21x versus 18.81x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 12.4%. ResMed, Inc.'s return on equity of 25.6% beat Insulet Corp.'s return on equity of 18.92%.

ResMed, Inc. has a consensus price target of $292.67, signalling upside risk potential of 13.56%. On the other hand Insulet Corp. has an analysts' consensus of $370.44 which suggests that it could grow by 43.47%. Given that Insulet Corp. has higher upside potential than ResMed, Inc., analysts believe Insulet Corp. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.400, suggesting its more volatile than the S&P 500 by 39.975%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.88%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are larger than Insulet Corp. quarterly revenues of $706.3M. ResMed, Inc.'s net income of $348.5M is higher than Insulet Corp.'s net income of $87.6M. Notably, ResMed, Inc.'s price-to-earnings ratio is 26.38x while Insulet Corp.'s PE ratio is 74.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.21x versus 7.41x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 14.18%. ResMed, Inc.'s return on equity of 25.6% beat Stryker Corp.'s return on equity of 14.06%.

ResMed, Inc. has a consensus price target of $292.67, signalling upside risk potential of 13.56%. On the other hand Stryker Corp. has an analysts' consensus of $425.68 which suggests that it could grow by 18.96%. Given that Stryker Corp. has higher upside potential than ResMed, Inc., analysts believe Stryker Corp. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 10.974%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.88%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.88 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. ResMed, Inc.'s net income of $348.5M is lower than Stryker Corp.'s net income of $859M. Notably, ResMed, Inc.'s price-to-earnings ratio is 26.38x while Stryker Corp.'s PE ratio is 46.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.21x versus 5.67x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 17.41%. ResMed, Inc.'s return on equity of 25.6% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

ResMed, Inc. has a consensus price target of $292.67, signalling upside risk potential of 13.56%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 43.73%. Given that West Pharmaceutical Services, Inc. has higher upside potential than ResMed, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.88%. West Pharmaceutical Services, Inc. offers a yield of 0.35% to investors and pays a quarterly dividend of $0.22 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. ResMed, Inc.'s net income of $348.5M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, ResMed, Inc.'s price-to-earnings ratio is 26.38x while West Pharmaceutical Services, Inc.'s PE ratio is 35.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.21x versus 5.81x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.